The individual intangible assets, excluding goodwill, which are material to the financial statements are:
| Carrying amount | Remaining amortisation period | |||||||||||||||||||||||
| 2017 | 2016 | 2015 | 2017 | 2016 | 2015 | |||||||||||||||||||
| £’000 | £’000 | £’000 | (years) | (years) | (years) | |||||||||||||||||||
| Midatech Pharma (Wales) Limited acquired IPRD |
9,300 | 10,800 | 10,800 | n/a in process | n/a in process | n/a in process | ||||||||||||||||||
| Midatech Pharma US, Inc., product and marketing rights |
1,995 | 3,557 | 15,570 | Between 1 and 3 | Between 1 and 4 | Between 2 and 5 | ||||||||||||||||||
| Zuplenz®
product and marketing rights |
2,122 | 2,316 | 2,508 | 11 | 12 | 13 | ||||||||||||||||||
| MTX110 acquired IPRD | 778 | - | - | n/a in process | - | - | ||||||||||||||||||
| 14,195 | 16,673 | 28,878 | ||||||||||||||||||||||